PBE vs. SBIO ETF Comparison

Comparison of PowerShares Dynamic Biotech & Genome (PBE) to ALPS Medical Breakthroughs ETF (SBIO)
PBE

PowerShares Dynamic Biotech & Genome

PBE Description

The PowerShares Dynamic Biotechnology & Genome Portfolio (Fund) is based on the Dynamic Biotech & Genome IntellidexSM Index (Intellidex Index). The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances biotechnology and genetic engineering and reseach. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

Grade (RS Rating)

Last Trade

$59.85

Average Daily Volume

12,380

Number of Holdings *

30

* may have additional holdings in another (foreign) market
SBIO

ALPS Medical Breakthroughs ETF

SBIO Description The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the Poliwogg Medical Breakthroughs IndexSM. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology and pharmaceutical companies that have one or more drugs in either Phase II or Phase III U.S. Food and Drug Administration clinical trials. It is non-diversified.

Grade (RS Rating)

Last Trade

$31.59

Average Daily Volume

13,852

Number of Holdings *

84

* may have additional holdings in another (foreign) market
Performance
Period PBE SBIO
30 Days -7.83% -11.35%
60 Days -7.38% -12.77%
90 Days -7.16% -0.65%
12 Months -5.00% 6.26%
6 Overlapping Holdings
Symbol Grade Weight in PBE Weight in SBIO Overlap
ACAD F 1.95% 1.89% 1.89%
CLDX D 2.92% 1.67% 1.67%
CPRX B 3.21% 1.23% 1.23%
MNKD D 3.29% 0.74% 0.74%
VCEL B 2.83% 1.54% 1.54%
XENE D 2.45% 2.1% 2.1%
PBE Overweight 24 Positions Relative to SBIO
Symbol Grade Weight
BMRN B 5.44%
NBIX C 5.23%
REGN C 5.0%
VRTX C 4.98%
GILD F 4.95%
AMGN B 4.93%
TECH F 4.91%
BIIB F 4.73%
EXEL A 3.16%
COLL C 3.15%
UTHR A 3.15%
HALO D 3.09%
TGTX D 3.06%
PTCT F 2.84%
DVAX D 2.74%
IONS D 2.69%
BPMC C 2.68%
QGEN D 2.66%
ITCI A 2.52%
RGEN D 2.39%
MYGN D 2.34%
FOLD D 2.24%
VCYT F 2.22%
EYPT D 2.21%
PBE Underweight 78 Positions Relative to SBIO
Symbol Grade Weight
CERE B -5.04%
VKTX B -4.79%
PCVX D -4.53%
RVMD A -4.01%
ALPN A -2.84%
ALKS F -2.67%
CRNX A -2.28%
AXSM F -2.19%
SWTX D -2.15%
IDYA D -2.04%
ACLX D -1.96%
IMCR D -1.79%
SMMT D -1.67%
CORT F -1.63%
DNLI F -1.62%
MRUS D -1.57%
VERA D -1.57%
RYTM D -1.56%
ARVN D -1.53%
NTLA F -1.41%
KROS D -1.4%
GLPG F -1.31%
GERN A -1.31%
RNA A -1.28%
SNDX D -1.22%
INBX C -1.1%
AGIO B -1.09%
EWTX D -1.04%
PTGX D -1.02%
RCUS F -0.97%
ZLAB F -0.96%
KURA D -0.95%
MORF F -0.94%
FDMT D -0.9%
TARS B -0.88%
VRNA F -0.88%
DAWN B -0.86%
IRWD D -0.83%
AKRO F -0.82%
DCPH D -0.81%
XNCR F -0.78%
PRTA F -0.77%
VIR F -0.76%
MIRM F -0.75%
MGNX B -0.7%
LQDA D -0.69%
VRDN F -0.64%
BCRX F -0.64%
MDXG F -0.62%
ZNTL F -0.61%
ETNB F -0.59%
SPRY B -0.59%
OPK B -0.57%
PLRX F -0.54%
ARCT F -0.54%
IRON F -0.49%
AUPH F -0.49%
KNSA D -0.47%
SVRA D -0.47%
AVTE B -0.44%
ALLO F -0.4%
OLMA F -0.4%
CMPS F -0.38%
ANAB D -0.38%
ALEC F -0.34%
MLYS D -0.33%
FULC D -0.31%
TVTX F -0.31%
REPL F -0.3%
BMEA F -0.29%
ITOS D -0.27%
AURA F -0.24%
AVXL F -0.23%
ENTA C -0.22%
INZY F -0.2%
RAPT F -0.19%
VNDA A -0.16%
RPHM B -0.04%
Compare ETFs